Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04, Bloomberg Earnings reports. The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 117.78% and a negative net margin of 874.41%.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 3.31% on Thursday, reaching $5.85. The company’s stock had a trading volume of 340,113 shares. The firm’s 50-day moving average price is $6.27 and its 200 day moving average price is $7.10. The company’s market cap is $293.78 million. Corbus Pharmaceuticals Holdings has a 52-week low of $2.95 and a 52-week high of $10.78.

A number of research analysts recently issued reports on the company. Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Saturday, May 6th. Cantor Fitzgerald set a $24.00 price objective on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a report on Wednesday. Finally, BidaskClub downgraded Corbus Pharmaceuticals Holdings from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $20.50.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Earnings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with's FREE daily email newsletter.